Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

NIH launches precision medicine trial to test new treatments for myeloid cancers

The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

23 Oct 2024

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

23 Oct 2024

Case Western Reserve University receives grant to investigate AML treatment for veterans

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve University are investigating a new approach to treat Acute Myeloid Leukemia (AML) in military Veterans.

15 Oct 2024

Evaluating allogeneic transplant for TP53 mutated acute myeloid leukemia

A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Transplant or no transplant for TP53 mutated AML."

12 Oct 2024

Gene therapy offers hope for children with cerebral adrenoleukodystrophy

Cerebral adrenoleukodystrophy (CALD) is a rare progressive, genetic brain disease that primarily presents in young boys, causing loss of neurological function and ultimately leading to early death.

9 Oct 2024

Future directions and challenges in harnessing NK cells against Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles

1 Oct 2024

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

17 Sep 2024

Study shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatments

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other standard-of-care therapies, according to a systematic review and meta-analysis.

11 Sep 2024

UC's Eric Vick receives major grants to advance research into combination therapy for leukemia

The University of Cincinnati Cancer Center's Eric Vick, MD, PhD, has been awarded a nearly $215,000 Career Development Award from the Leukemia and Lymphoma Society (LLS) and a $50,000 American Society of Clinical Oncology (ASCO) Young Investigator Award to continue research into a combination therapy treatment for acute myeloid leukemia (AML).

6 Sep 2024

Investigating inflammatory memory in hematopoietic stem cells within the AML niche

A new research perspective was published in Oncotarget's Volume 15 on September 4, 2024, entitled, "Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche."

5 Sep 2024

Leukemia cells depend on P-bodies for growth and survival

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth.

21 Aug 2024

Breakthrough in acute myeloid leukemia treatment targets stem cells

Acute myeloid leukemia is one of the deadliest cancers. Leukemic stem cells responsible for the disease are highly resistant to treatment.

24 Jul 2024

DDX41: A unique player in myeloid leukemogenesis

A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, "DDX41 and its unique contribution to myeloid leukemogenesis."

19 Jul 2024

$Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia$

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient's organ functions.

18 Jul 2024

Targeted gene therapy may reduce AML burden and protect the heart from cardiotoxicity

Researchers from the University of Missouri School of Medicine found that a targeted gene therapy may make acute myeloid leukemia (AML) more sensitive to chemotherapy, while also protecting the heart against toxicity often caused by cancer treatments.

27 Jun 2024

New research center delves into ubiquitin's role in cancer

The German Research Foundation (DFG) has now approved a new Collaborative Research Centre in the search for innovative therapies against cancer: Researchers from the Technical University of Munich (TUM), Goethe University Frankfurt and Julius-Maximilians-Universität Würzburg (JMU) have joined forces for this purpose.

31 May 2024

Genomic evidence of prenatal origins in childhood acute myeloid leukemia

A team of researchers from the Institute of Oncology of the University of Oviedo (IUOPA), the Josep Carreras leukemia Research Institute, the University of Barcelona and the Centre for Biomedical Research in Cancer Network (CIBERONC) have demonstrated that some childhood leukemia originate during embryonic development, although they do not manifest after a few months after birth.

30 May 2024

Acute Myeloid Leukemia News and Research

Further Reading